For example, L-asparaginase with low intrinsic L-glutaminase activity or high stability have been screened to reduce the side effects associated with high L-glutaminase activity during the treatment of ALL, thereby extending the potential scope for in vivo and in vitro applications [7, 8]. This evidence concerns the gene GLS2 and acute lymphoblastic leukemia.